A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer
CDAK539A12103
Phase 1 other active
Quick answer
A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer for Advanced Malignancies and Hepatic Impairment is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Advanced Malignancies and Hepatic Impairment
- Phase
- Phase 1
- Modality
- other
- Status
- active